In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 1, 1998, Pages 91-94

  Oakley, K L ^a   Moore, C B ^b   Denning, D W ^a,c  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS; CONTROLLED STUDY; FUNGICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLUS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 0031819776     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.1.91     Document Type: Article

References (9)

1. Bodey, G., Bueltmann, B., Duguid, W., Gibbs, D., Hanak, H., Hotchi, M. et al. (1992). Fungal infections in cancer patients: an international autopsy survey. European Journal of Clinical Microbiology and Infectious Diseases 11, 99-109.
2. Groll, A. H., Shah, P. M., Mentzel, C., Schneider, M., Just-Nuebling, G. & Huebner, K. (1996). Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. Journal of Infection 33, 23-32.
3. Hood, S. & Denning, D. W. (1996). Treatment of fungal infection in AIDS. Journal of Antimicrobial Chemotherapy 37, Suppl. B, 71-85.
4. Barry, A. L. & Brown, S. D. (1996). In vitro studies of two triazole antifungal agents (voriconazole [UK-109496] and fluconazole) against Candida species. Antimicrobial Agents and Chemotherapy 40, 1948-9.
5. Radford, S. A., Johnson, E. M. & Warnock, D. W. (1997). In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrobial Agents and Chemotherapy 41, 841-3.
6. Sutton, D. A., Fothergill, A. W., Barchiesi, F. J. & Rinaldi, M. G. (1996). In vitro activity of voriconazole against dimorphic fungi. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996, Abstract F85, p. 114. American Society for Microbiology, Washington, DC.
7. Denning, D. W., Del Favero, A., Gluckman, E. Norfolk, D., Ruhnke, M., Yonren, S. et al. (1995). UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F80, p. 126. American Society for Microbiology, Washington, DC.
8. Dupont, B., Denning, D. W., Lode, H., Yonren, S., Troke, P. & Sarantis, N. (1995). UK 109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F81, p. 127. American Society for Microbiology, Washington, DC.
9. Denning, D. W., Radford, S. A., Oakley, K. L., Hall, L., Johnson, E. M. & Warnock, D. W. (1997). Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. Journal of Antimicrobial Chemotherapy 40, 401-14.